Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clearance of NRL972 in Patients Undergoing Alcohol Withdrawal
2007-004663-22Phase 2Completed
- Sponsor
- Norgine
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorescein lisicol in alcoholic liver disease (ALD), sponsored by Norgine. Primary endpoint: Change in NRL972 clearance over 4 weeks. Started May 2008; status: completed.
02
Drugs
fluorescein lisicol
03
Conditions
alcoholic liver disease (ALD)
Beyond the preview
Go deeper on 2007-004663-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004663-22.